This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Although the cause of ALS remains enigmatic, plausible hypotheses have been generated and new facts are continuously presented to explain the disease process in ALS, as have been summarized in this colloquium. The likelihood that several drugs will be effective in treating ALS is a reality. At present, the first drug available by prescription for ALS, riluzole, appears to have only modest effects in prolonging survival. A consensus has developed that a key strategy for increasing benefit is the treatment of ALS patients with a combination of drugs that are effective individually to achieve additive or synergistic benefits. In fact, a combination of several drugs is the standard practice in the treatment of advanced cancers and infectious diseases. In this report, we review the preclinical data supporting combination treatment for ALS and discuss the issues that need to be addressed with drug combination treatment of patients with ALS.
The effects of combined neurotrophic factors in tissue cultures.
Motor neuron survival in chick embryonic tissue culture is only 4.8% in the control medium, whereas the percentage of the survival increases to 14.5% when insulin-like growth factor-I (IGF-I) is added, 51.9% with basic fibroblast growth factor (bFGF), and 60.7% with ciliary neurotrophic factor (CNTF). [1] When these trophic molecules are combined in the culture media, the percentage of motor neuron survival rises to 76.1% with a combination of bFGF and IGF-I, 87% with CNTF and IGF-I, and 98.2% with bFGF and CNTF. A combination of all three trophic factors (bFGF, IGF-I, and CNTF), however, does not increase the survival further. Concerning the survival of in vitro motor neurons, a combination of bFGF and CNTF appears to be most effective. [1] Although these studies demonstrate a partially additive effect of the combination, [1] similar studies have shown that a combination of CNTF and bFGF results in survival-promoting effects that are more than …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.